叶酸受体
医学
卵巢癌
单克隆抗体
抗体-药物偶联物
癌症
癌症研究
靶向治疗
抗体
肿瘤科
药品
生物信息学
药理学
内科学
免疫学
癌细胞
生物
作者
Jia Mai,Limei Wu,Ling Yang,Tongwen Sun,Xiaojuan Liu,Rutie Yin,Yongmei Jiang,Jie Li,Qintong Li
标识
DOI:10.3389/fimmu.2023.1254532
摘要
Epithelial ovarian cancer (EOC) is the deadliest gynecological cancer, and presents a major clinical challenge due to limited treatment options. Folate receptor alpha (FRα), encoded by the FOLR1 gene, is an attractive therapeutically target due to its prevalent and high expression in EOC cells. Recent basic and translational studies have explored several modalities, such as antibody-drug conjugate (ADC), monoclonal antibodies, small molecules, and folate-drug conjugate, to exploit FRα for EOC treatment. In this review, we summarize the function of FRα, and clinical efficacies of various FRα-based therapeutics. We highlight mirvetuximab soravtansine (MIRV), or Elahere (ImmunoGen), the first FRα-targeting ADC approved by the FDA to treat platinum-resistant ovarian cancer. We discuss potential mechanisms and management of ocular adverse events associated with MIRV administration.
科研通智能强力驱动
Strongly Powered by AbleSci AI